JP2019523253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523253A5 JP2019523253A5 JP2019503225A JP2019503225A JP2019523253A5 JP 2019523253 A5 JP2019523253 A5 JP 2019523253A5 JP 2019503225 A JP2019503225 A JP 2019503225A JP 2019503225 A JP2019503225 A JP 2019503225A JP 2019523253 A5 JP2019523253 A5 JP 2019523253A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- compound according
- crystalline form
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 108010010369 HIV Protease Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 CC[C@@](COC)Oc1cc(C(Nc2nc(C*3OCCCO3)c[s]2)=O)cc(Oc(cc2)cnc2S(C)(=O)=O)c1 Chemical compound CC[C@@](COC)Oc1cc(C(Nc2nc(C*3OCCCO3)c[s]2)=O)cc(Oc(cc2)cnc2S(C)(=O)=O)c1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365520P | 2016-07-22 | 2016-07-22 | |
| US62/365,520 | 2016-07-22 | ||
| PCT/US2017/043199 WO2018017910A1 (en) | 2016-07-22 | 2017-07-21 | Glucokinase activators and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523253A JP2019523253A (ja) | 2019-08-22 |
| JP2019523253A5 true JP2019523253A5 (enExample) | 2020-08-27 |
| JP7072557B2 JP7072557B2 (ja) | 2022-05-20 |
Family
ID=59501613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503225A Active JP7072557B2 (ja) | 2016-07-22 | 2017-07-21 | グルコキナーゼ活性化剤およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10604541B2 (enExample) |
| EP (1) | EP3487862A1 (enExample) |
| JP (1) | JP7072557B2 (enExample) |
| KR (1) | KR102513342B1 (enExample) |
| CN (1) | CN109715637B (enExample) |
| MA (1) | MA45714A (enExample) |
| WO (1) | WO2018017910A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL325046A (en) * | 2023-06-06 | 2026-02-01 | Hua Medicine Shanghai Ltd | Activates glucokinase for cognitive disorders and neurodegenerative diseases |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594113A (en) | 1988-06-23 | 1997-01-14 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| EP1607401A1 (en) | 2000-03-08 | 2005-12-21 | Metabasis Therapeutics, Inc. | Novel aryl fructose-1,6-Bisphosphatase inhibitors |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
| DK2060266T3 (da) | 2004-03-17 | 2011-11-14 | 7Tm Pharma As | Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb |
| MXPA06012683A (es) | 2004-05-03 | 2007-01-16 | Hoffmann La Roche | Derivados de indolilo como moduladores de receptor x del higado. |
| EP1758611A2 (en) | 2004-06-17 | 2007-03-07 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| CN101490064B (zh) * | 2006-07-06 | 2012-10-10 | 百时美施贵宝公司 | 新颖葡萄糖激酶活化剂及其使用方法 |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| GB0619325D0 (en) | 2006-09-30 | 2006-11-08 | Univ Strathclyde | New compounds |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| US8222285B2 (en) * | 2007-06-11 | 2012-07-17 | Bristol-Myers Squibb Company | 1,3-dihydroxy substituted phenylamide glucokinase activators |
| CN101808995A (zh) | 2007-07-27 | 2010-08-18 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| CA2695583A1 (en) * | 2007-08-13 | 2009-02-19 | Metabasis Therapeutics, Inc. | Novel activators of glucokinase |
| AR068540A1 (es) | 2007-09-28 | 2009-11-18 | Merck & Co Inc | Metodos de produccion de un derivado de pirazol-3-il-benzamida. |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| GEP20135793B (en) | 2008-09-11 | 2013-03-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
| US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
| EP2558461B1 (en) * | 2010-04-14 | 2015-12-02 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP2013544787A (ja) | 2010-10-13 | 2013-12-19 | タケダ カリフォルニア インコーポレイテッド | アザインダゾール誘導体の調製方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2016040225A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
-
2017
- 2017-07-21 CN CN201780057682.1A patent/CN109715637B/zh active Active
- 2017-07-21 EP EP17746324.7A patent/EP3487862A1/en not_active Withdrawn
- 2017-07-21 KR KR1020197004835A patent/KR102513342B1/ko active Active
- 2017-07-21 JP JP2019503225A patent/JP7072557B2/ja active Active
- 2017-07-21 US US16/318,173 patent/US10604541B2/en active Active
- 2017-07-21 MA MA045714A patent/MA45714A/fr unknown
- 2017-07-21 WO PCT/US2017/043199 patent/WO2018017910A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015145426A5 (enExample) | ||
| JP2018115191A5 (enExample) | ||
| JP2024071370A5 (enExample) | ||
| RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| JP2010529203A5 (enExample) | ||
| JP2022502500A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2018521121A5 (enExample) | ||
| JP2009542717A5 (enExample) | ||
| JP2010526145A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| RU2009121756A (ru) | Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk) | |
| JP2010514832A5 (enExample) | ||
| RU2011151611A (ru) | Композиции для модуляции киназного каскада и способы их применения | |
| RU2015134420A (ru) | Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты | |
| JP2009506014A5 (enExample) | ||
| JP2016500063A5 (enExample) | ||
| JP2020528913A5 (enExample) | ||
| RU2002113169A (ru) | Измельченная форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| RU2015142255A (ru) | Фармацевтическое комбинированное лекарственное средство | |
| RU2002113450A (ru) | Кристаллическая форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| JP2016510768A5 (enExample) | ||
| JP2014144916A (ja) | ２−アシルアミノチアゾール化合物の結晶 | |
| CA2600203A1 (en) | New salt and polymorphs of a dpp-iv inhibitor | |
| RU2017131522A (ru) | (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота |